Last reviewed · How we verify
Experimental: mXELOX plus cetuximab
mXELOX plus cetuximab combines modified capecitabine/oxaliplatin chemotherapy with an EGFR-targeting monoclonal antibody to inhibit tumor cell proliferation and survival.
mXELOX plus cetuximab combines modified capecitabine/oxaliplatin chemotherapy with an EGFR-targeting monoclonal antibody to inhibit tumor cell proliferation and survival. Used for Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type).
At a glance
| Generic name | Experimental: mXELOX plus cetuximab |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Combination chemotherapy plus monoclonal antibody |
| Target | EGFR (cetuximab component); DNA synthesis (capecitabine/oxaliplatin component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
mXELOX is a modified version of the XELOX regimen (capecitabine and oxaliplatin), a combination chemotherapy used in colorectal cancer. Cetuximab is a chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR) and blocks ligand-induced signaling, preventing tumor cell growth. Together, the regimen targets both DNA replication (via chemotherapy) and EGFR-driven proliferation pathways.
Approved indications
- Metastatic colorectal cancer (likely EGFR-expressing, KRAS wild-type)
Common side effects
- Neutropenia
- Diarrhea
- Hand-foot skin reaction
- Acneiform rash
- Nausea/vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |